NOTABLE LABS LTD (NTBL) Stock Fundamental Analysis

NASDAQ:NTBL • IL0012002452

0.2479 USD
-0.09 (-27.68%)
At close: Oct 22, 2024
0.2456 USD
0 (-0.93%)
After Hours: 10/22/2024, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

NTBL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. NTBL may be in some trouble as it scores bad on both profitability and health. NTBL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NTBL has reported negative net income.
  • NTBL had a negative operating cash flow in the past year.
  • NTBL had negative earnings in each of the past 5 years.
  • In the past 5 years NTBL always reported negative operating cash flow.
NTBL Yearly Net Income VS EBIT VS OCF VS FCFNTBL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • NTBL's Return On Assets of -152.09% is on the low side compared to the rest of the industry. NTBL is outperformed by 86.15% of its industry peers.
  • The Return On Equity of NTBL (-232.90%) is worse than 71.23% of its industry peers.
Industry RankSector Rank
ROA -152.09%
ROE -232.9%
ROIC N/A
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
NTBL Yearly ROA, ROE, ROICNTBL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

  • Looking at the Gross Margin, with a value of 37.70%, NTBL is in the better half of the industry, outperforming 76.91% of the companies in the same industry.
  • NTBL's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NTBL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
NTBL Yearly Profit, Operating, Gross MarginsNTBL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • NTBL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NTBL has more shares outstanding
  • The debt/assets ratio for NTBL is higher compared to a year ago.
NTBL Yearly Shares OutstandingNTBL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
NTBL Yearly Total Debt VS Total AssetsNTBL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -16.80, we must say that NTBL is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -16.80, NTBL is not doing good in the industry: 84.55% of the companies in the same industry are doing better.
  • NTBL has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • NTBL has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC10.75%
NTBL Yearly LT Debt VS Equity VS FCFNTBL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

  • NTBL has a Current Ratio of 2.77. This indicates that NTBL is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NTBL (2.77) is worse than 68.56% of its industry peers.
  • NTBL has a Quick Ratio of 2.77. This indicates that NTBL is financially healthy and has no problem in meeting its short term obligations.
  • NTBL has a worse Quick ratio (2.77) than 67.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
NTBL Yearly Current Assets VS Current LiabilitesNTBL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 65.56% over the past year.
  • NTBL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.79%.
  • The Revenue for NTBL have been decreasing by -12.08% on average. This is quite bad
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NTBL will show a very negative growth in Earnings Per Share. The EPS will decrease by -63.21% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NTBL Yearly Revenue VS EstimatesNTBL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
NTBL Yearly EPS VS EstimatesNTBL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NTBL. In the last year negative earnings were reported.
  • Also next year NTBL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTBL Price Earnings VS Forward Price EarningsNTBL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTBL Per share dataNTBL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • NTBL's earnings are expected to decrease with -63.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.21%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NTBL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NOTABLE LABS LTD

NASDAQ:NTBL (10/22/2024, 8:00:02 PM)

After market: 0.2456 0 (-0.93%)

0.2479

-0.09 (-27.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14
Earnings (Next)11-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners16.5%
Ins Owner Change0%
Market Cap2.39M
Revenue(TTM)313.00K
Net Income(TTM)-16.74M
Analysts80
Price Target9.18 (3603.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.38%
Min EPS beat(2)-25.98%
Max EPS beat(2)-4.77%
EPS beat(4)0
Avg EPS beat(4)-294.73%
Min EPS beat(4)-1133.4%
Max EPS beat(4)-4.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-31.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.65
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-6.91
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.03
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.09%
ROE -232.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.7%
FCFM N/A
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
F-Score1
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.83%
Cap/Sales 25.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -16.8
F-Score1
WACC10.75%
ROIC/WACCN/A
Cap/Depr(3y)72.79%
Cap/Depr(5y)45.66%
Cap/Sales(3y)111.54%
Cap/Sales(5y)70.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.33%
OCF growth 3YN/A
OCF growth 5YN/A

NOTABLE LABS LTD / NTBL FAQ

What is the ChartMill fundamental rating of NOTABLE LABS LTD (NTBL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NTBL.


What is the valuation status of NOTABLE LABS LTD (NTBL) stock?

ChartMill assigns a valuation rating of 0 / 10 to NOTABLE LABS LTD (NTBL). This can be considered as Overvalued.


What is the profitability of NTBL stock?

NOTABLE LABS LTD (NTBL) has a profitability rating of 1 / 10.


What is the financial health of NOTABLE LABS LTD (NTBL) stock?

The financial health rating of NOTABLE LABS LTD (NTBL) is 3 / 10.


What is the earnings growth outlook for NOTABLE LABS LTD?

The Earnings per Share (EPS) of NOTABLE LABS LTD (NTBL) is expected to decline by -81.59% in the next year.